BioSpace News Archive

Taysha Gene Therapies, Inc. announced the pricing of an underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $2.00 per share.

The Board of Directors of PerkinElmer, Inc. declared a regular quarterly dividend of $0.07 per share of common stock.

Milla Pharmaceuticals Inc., a subsidiary of the Alter Pharma Group, announced it has filed its ANDA Application with Paragraph IV Certification on July 20th, 2022 and received a Paragraph IV Acknowledgement Letter and Receipt from FDA on August 31st, 2022.

Cali Biosciences Co., Ltd. (hereinafter referred to as “Cali Biosciences”), a biopharmaceutical company focused on the research and development of innovative drugs, announced two major milestones for CPL-01, its long-acting ropivacaine for post-operative analgesia and opioid elimination/reduction.

CANbridge Pharmaceuticals Inc. announced that the company’s partner Mirum Pharmaceuticals, Inc. reported positive topline data from its Phase 3 MARCH study evaluating the safety and efficacy of LIVMARLI® oral solution in patients with progressive familial intrahepatic cholestasis.

Antengene Corporation Limited announced that it will host its R&D Day for the investment community on November 15th and November 17th since its inception to review Antengene’s R&D strategy and pipeline, the commercial launch of XPOVIO® underway in China and other markets in Asia, and other important company updates.